These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38809627)

  • 1. Investigating Radiotherapy Effects on PD-L1 Expression in Circulating Tumor Cells: An Exploratory Study.
    Rafli R; Harahap WA; Gondhowiardjo S; Ekaputra A
    Asian Pac J Cancer Prev; 2024 May; 25(5):1559-1566. PubMed ID: 38809627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
    Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
    Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
    PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
    Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy.
    Adams DL; Adams DK; He J; Kalhor N; Zhang M; Xu T; Gao H; Reuben JM; Qiao Y; Komaki R; Liao Z; Edelman MJ; Tang CM; Lin SH
    Clin Cancer Res; 2017 Oct; 23(19):5948-5958. PubMed ID: 28679765
    [No Abstract]   [Full Text] [Related]  

  • 8. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
    Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
    Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
    Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
    Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer.
    Wang W; Zhang T
    Future Oncol; 2021 May; 17(13):1625-1635. PubMed ID: 33726500
    [No Abstract]   [Full Text] [Related]  

  • 12. Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
    Wang HL; Wu JQ; Wang Y; Yu J; Mao XN; Li ZR; Niu HR; Jin CL; Wang XJ; Yan ZH; Yi L; Yang B; Wei PJ; Zhang HT; Zhang SC
    Neoplasma; 2021 Jul; 68(4):823-831. PubMed ID: 34097427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
    Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M
    Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
    Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
    Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
    Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
    Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.
    Zhou Y; Zhou J; Hao X; Shi H; Li X; Wang A; Hu Z; Yang Y; Jiang Z; Wang T
    Breast Cancer Res Treat; 2023 Jul; 200(2):281-291. PubMed ID: 37227611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.
    Liu Q; Zhao C; Jiang P; Liu D
    Medicine (Baltimore); 2021 Jul; 100(29):e26674. PubMed ID: 34398034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
    Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
    Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
    Dhar M; Wong J; Che J; Matsumoto M; Grogan T; Elashoff D; Garon EB; Goldman JW; Sollier Christen E; Di Carlo D; Kulkarni RP
    Sci Rep; 2018 Feb; 8(1):2592. PubMed ID: 29416054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.